JUN 11, 2026 · JOURNAL ARTICLE
Immunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8)-like influenza vaccine in adults: Phase 1/2, observer-blinded, randomized trial.
Human Vaccines & Immunotherapeutics
Phase 1/2 trial demonstrating that AS03-adjuvanted H5N8 vaccine met FDA immunogenicity criteria with acceptable safety in adults, but lacks efficacy data and comparative effectiveness evidence needed for practice-changing claims.
Reported
Sample size (vaccinated)518
Primary endpoint timepointday 43
Hemagglutinin antigen dose tested3.75 or 7.50 µg